Keene & Associates Inc. Has $2.52 Million Position in Pfizer Inc. (NYSE:PFE)

Keene & Associates Inc. trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 15.1% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 95,073 shares of the biopharmaceutical company’s stock after selling 16,929 shares during the period. Pfizer comprises 2.0% of Keene & Associates Inc.’s holdings, making the stock its 25th largest position. Keene & Associates Inc.’s holdings in Pfizer were worth $2,522,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Good Life Advisors LLC grew its stake in shares of Pfizer by 27.1% in the fourth quarter. Good Life Advisors LLC now owns 71,410 shares of the biopharmaceutical company’s stock valued at $1,895,000 after buying an additional 15,211 shares in the last quarter. Strata Wealth Advisors LLC lifted its stake in Pfizer by 34.6% in the fourth quarter. Strata Wealth Advisors LLC now owns 15,162 shares of the biopharmaceutical company’s stock valued at $402,000 after acquiring an additional 3,897 shares during the last quarter. Convergence Investment Partners LLC grew its position in shares of Pfizer by 673.9% in the 4th quarter. Convergence Investment Partners LLC now owns 107,413 shares of the biopharmaceutical company’s stock valued at $2,850,000 after acquiring an additional 93,533 shares during the period. Plan Group Financial LLC increased its stake in shares of Pfizer by 14.3% during the 4th quarter. Plan Group Financial LLC now owns 35,789 shares of the biopharmaceutical company’s stock worth $949,000 after purchasing an additional 4,472 shares during the last quarter. Finally, Allied Investment Advisors LLC lifted its stake in Pfizer by 1.4% in the 4th quarter. Allied Investment Advisors LLC now owns 262,737 shares of the biopharmaceutical company’s stock valued at $6,970,000 after purchasing an additional 3,534 shares during the last quarter. Institutional investors own 68.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have weighed in on PFE. Guggenheim reissued a “buy” rating and set a $33.00 price target on shares of Pfizer in a research report on Monday, February 10th. Bank of America restated a “neutral” rating and issued a $29.00 price target on shares of Pfizer in a research note on Tuesday, December 10th. Citigroup reduced their price objective on shares of Pfizer from $30.00 to $29.00 and set a “neutral” rating for the company in a research report on Tuesday, January 28th. Wolfe Research initiated coverage on shares of Pfizer in a research report on Friday, November 15th. They issued an “underperform” rating and a $25.00 price objective on the stock. Finally, Truist Financial reduced their target price on shares of Pfizer from $36.00 to $32.00 and set a “buy” rating for the company in a report on Wednesday, December 18th. One equities research analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have assigned a buy rating and two have issued a strong buy rating to the company’s stock. According to MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $31.92.

Pfizer Trading Up 0.1 %

Shares of NYSE:PFE opened at $25.56 on Wednesday. The company has a market capitalization of $144.82 billion, a P/E ratio of 18.12, a P/E/G ratio of 0.63 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73. The business’s 50 day simple moving average is $26.26 and its 200 day simple moving average is $27.46. Pfizer Inc. has a 1 year low of $24.48 and a 1 year high of $31.54.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.48 by $0.15. Pfizer had a return on equity of 19.47% and a net margin of 12.62%. The company had revenue of $17.76 billion for the quarter, compared to analyst estimates of $17.26 billion. During the same period in the prior year, the firm posted $0.10 EPS. Pfizer’s quarterly revenue was up 24.7% on a year-over-year basis. On average, research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Stockholders of record on Friday, January 24th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.73%. The ex-dividend date is Friday, January 24th. This is an increase from Pfizer’s previous quarterly dividend of $0.42. Pfizer’s dividend payout ratio is 121.99%.

Insider Buying and Selling

In other Pfizer news, Director Ronald E. Blaylock acquired 19,457 shares of the company’s stock in a transaction that occurred on Thursday, February 13th. The stock was acquired at an average cost of $25.65 per share, for a total transaction of $499,072.05. Following the transaction, the director now directly owns 27,707 shares in the company, valued at $710,684.55. This represents a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is available through this link. 0.06% of the stock is currently owned by company insiders.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.